沙利度胺+化疗对晚期肺癌患者血清VEGF和TNF-a的影响

摘要

Objective To observe the thalidomide and chemotherapy ef icacy of vascular endothelialgrowth factor(VEGF) and tumor necrosis factor(TNF-a) in the serum of advanced non-smal cell lung cancer. Methods 40 cases of advanced non-smal celllung cancer were randomly divided into groups of thalidomide and GP chemotherapy (treatment group) and GP chemotherapy (control group). Clinical observation on treatment of 4 cycles . content by ELISA method for detection of VEGF and TNF-a before and after treatment in peripheral serum. Results The remission rate in the treatment group was 65%, control group 55%, There was no significant dif erence between two groups, but two groups had no statistical difference, but the content of serum VEGF and TNF-a decreased significantly ( <0.05). Conclusion Thalidomide and chemotherapy can significantly reduce VEGF and TNF-a in serum of patients with advanced lung cancer level.%目的探讨沙利度胺+化疗对晚期非小细胞肺癌患者血清血管内皮生长因子(VEGF)和肿瘤坏死因子(TNF-a)的影响。方法将40例非小细胞肺癌晚期患者随机分为两组，治疗组用沙利度胺+GP方案化疗，对照组用单纯的GP方案化疗，治疗4个周期后观察疗效，治疗前后用ELISA方法检测周围血清中VEGF和TNF-a的含量。结果治疗组缓解率为65%，对照组为55%，两组比较无统计学差异，但治疗组血清VEGF和TNF-a的含量有明显下降，(<0.05)。结论沙利度胺+化疗可明显减轻对晚期肺癌患者血清VEGF和TNF-a的水平。